Reason for request
Inclusion on list of products for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of ACTILYSE 2 mg is substantial. |
Clinical Added Value
| minor |
ACTILYSE 2 mg provides a minor improvement in actual benefit (IAB IV) in terms of efficacy in comparison with ACTOSOLV UROKINASE. |
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
tGUn3nyYuGpAfd3x
Listen
